Gapping down
In reaction to earnings/guidance:
- TBI -15.3%, SPOT -6.8%, MEDP -6%, DOV -5.5%, ALK -5.1%, DHR -5.1%, IRDM -5.1%, CDNS -4.1%, RTX -3.1%, NWE -2.8%, IBTX -2.6%, CCK -2.2%, HXL -2.1%, AGYS -2%, AVY -2%, IVZ -2%, MCO -1.7%, HUBB -1.4%, GLW -1.3%, MLI -0.9%, NUE -0.7%, HRI -0.7%, AGNC -0.6%, PII -0.6%
Other news:
- STOK -39.7% (reports Safety & Efficacy Data from Patients Treated with STK-001 in the Phase 1/2a Studies (MONARCH & ADMIRAL) and the SWALLOWTAIL Open-Label Extension (OLE) Study in Children and Adolescents with Dravet Syndrome)
- TARS -11.5% (FDA Approves XDEMVY (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis)
- SOUN -8.2% (files $400 mln mixed shelf)
- AMC -8.2% (moving lower potentially due to court filing)
- VRDN -0.9% (stock offering)
Analyst comments:
- RXT -7% (downgraded to Sell from Neutral at Citigroup)
- KOD -5.1% (downgraded to Underweight from Neutral at JP Morgan)
- PGR -1.7% (downgraded to Underweight from Equal-Weight at Morgan Stanley)
- DIS -0.8% (downgraded to Underweight from Neutral at Atlantic Equities)
- GS -0.5% (downgraded to Neutral from Buy at Citigroup)